Abiopharma

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçets Disease Published in Rheumatology (Oxford)

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

Edwards Lifesciences Corp - Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion

Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Halozyme - U.S. FDA Approves RYBREVANT FASPRO™(amivantamab and hyaluronidase-lpuj) Co-Formulated withENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia